The Zhitong Finance App learned that CITIC Lyon released a research report stating that it will raise the target price of Fosun Pharmaceuticals (02196,600196.SH) H shares by 1.9%, from HK$26.6 to HK$27.1, while also raising the target price for A-shares to maintain the “outperform the market” rating. The bank said that Fosun Pharma's third quarter results were basically in line with expectations, and steady growth in sales of innovative products led to an increase in profit margins.

Looking ahead, the results of the global phase III clinical trial of AR1001 for the treatment of Alzheimer's disease will be a key catalyst in the near future. Furthermore, the continued commercialization process of serplulimab (serplulimab) in China and regulatory advances in the US and Japan also provided additional growth options for the company.

Disclaimer:Webull uses external vendor Google Translation Service for news translations where we endeavour to ensure these are correct, however, we recommend that you please double-check this information accordingly. Webull is not responsible for translation errors or issues.